Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
Open Access
- 2 September 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 34 (40), 3128-3136
- https://doi.org/10.1093/eurheartj/eht371
Abstract
Patients hospitalized for acute heart failure (AHF) differ with respect of many clinical characteristics which may influence their prognosis and response to treatment. We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial. Subgroups were based on pre-specified covariates (age, sex, race, geographic region, estimated glomerular filtration rate, time from presentation to randomization, baseline systolic blood pressure, history of diabetes, atrial fibrillation, ischaemic heart disease, cardiac devices, i.v. nitrates at randomization). Other covariates which may modify the efficacy of AHF treatment were also analysed. Subgroup analyses did not show any difference in the effects of serelaxin vs. placebo on dyspnoea relief or on the incidence of cardiovascular death or rehospitalizations for heart failure or renal failure at 60 days. Nominally significant interactions between some patient subgroups and the effects of serelaxin on 180 days cardiovascular and all-cause mortality were noted but should be interpreted cautiously due to the number of comparisons and the low incidence of deaths in the subgroups at lower risk. The effects of serelaxin vs. placebo appeared to be similar across subgroups of patients in RELAX-AHF.This publication has 29 references indexed in Scilit:
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012European Journal of Heart Failure, 2012
- Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term OutcomesCirculation: Heart Failure, 2011
- Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart FailureThe New England Journal of Medicine, 2010
- Clinical Trials of Pharmacological Therapies in Acute Heart Failure SyndromesCirculation: Heart Failure, 2010
- Cardiovascular effects of relaxin: from basic science to clinical therapyNature Reviews Cardiology, 2009
- Relaxin, a pleiotropic vasodilator for the treatment of heart failureHeart Failure Reviews, 2008
- Transition From Chronic Compensated to Acute Decompensated Heart FailureCirculation, 2008
- Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart FailureCirculation, 2007
- Impact of Early Initiation of Intravenous Therapy for Acute Decompensated Heart Failure on Outcomes in ADHERECardiology, 2006
- Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problemsStatistics in Medicine, 2002